Search
Cumberland Pharmaceuticals Inc
CPIXAdd to Watchlist
7.320USD
+0.130+1.81%
Close 09-18 16:00（ET）
109.83MMarket Cap
LossP/E TTM
More Details of Cumberland Pharmaceuticals Inc Company
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Cumberland Pharmaceuticals Inc Profile
Ticker SymbolCPIX
Company nameCumberland Pharmaceuticals Inc
IPO dateAug 11, 2009
CEOKazimi (A. J)
Number of employees91
Security typeOrdinary Share
Fiscal year-endAug 11
Address1600 West End Avenue, Suite 1300
CityNASHVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code37203
Phone18774842700
Websitehttps://www.cumberlandpharma.com/
Ticker SymbolCPIX
IPO dateAug 11, 2009
CEOKazimi (A. J)
Company Executives of Cumberland Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
16.33K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
302.34K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
46.86K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
35.11K
--
FAQs
Who are the top five shareholders of Cumberland Pharmaceuticals Inc?
The top five shareholders of Cumberland Pharmaceuticals Inc are: Mr. Kenneth J. Krogulski
How many institutions hold shares of Cumberland Pharmaceuticals Inc (CPIX)?
As of 2026Q1, 59 institutions hold shares of Cumberland Pharmaceuticals Inc, with a combined market value of approximately 2.95M, accounting for 19.66% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1007470.00.
What is the biggest source of revenue for Cumberland Pharmaceuticals Inc?
In 2026Q1, the Sancuso business generated the highest revenue for Cumberland Pharmaceuticals Inc, amounting to 2.93M and accounting for 32.07% of total revenue.